Full text is available at the source.
Abstract
Lipedema is a chronic condition that primarily affects women and is characterized by bilateral, symmetrical fat deposition in the lower limbs.
- Pharmacological treatments for lipedema are currently limited.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer therapeutic benefits.
- Dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs) could also provide potential advantages.
- These interventions are associated with effects on weight, metabolism, pain, and inflammation.
Simplified